



## **PACIFIC THERAPEUTICS LTD. ISSUES STOCK OPTIONS TO INVESTOR RELATIONS CONSULTANT AND DIRECTOR**

**VANCOUVER, BC, Canada – February 24, 2015 – Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the “Company”)** is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company’s lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are \$1 billion plus market opportunities.

The Company proposes to issue a total of 400,000 options to purchase common shares to a director and a consultant under the 2014 stock option plan as approved at the Company’s previous annual general meeting. The issuance of the options is subject to regulatory approval.

The Company has entered into an agreement with Small Cap Invest Ltd. (Small-Cap), a Frankfurt-based financial service company. Serving as a contractor, Small-Cap will develop investor and public relations across Europe, and use an impressive breadth of experience to ultimately facilitate the commercialization of the Company’s therapies in European markets.

Small-Cap has a self-professed focus on the discovery of undervalued and promising growth companies, and serves these companies by increasing visibility and accessing capital through an experienced network of investors. The team has an extensive background in the European financial community and uses this to facilitate the listing of stocks, introductions to investors through road shows and trade shows, securing public funding and private financing, and a variety of other business development activities. Small-Cap has also shown itself to be effective at the translation and dissemination of client materials, including technical documents and press releases, to a broad European audience to increase awareness of a company's activities.

Small-Cap Invest Ltd. has agreed provide these investor relations services for 6 months. Small-Cap will receive 250,000 of the above stock options. The options may be exercised at a price of \$0.25 per share for a period ranging from 3 years. Small-cap invest will be responsible for both inbound and outbound investor relations activities in Europe.

“Pacific Therapeutics is one of the greatest investment opportunities we have recently come across, and have an outstanding team and technology,” says Alexander Friedrich, the founder and CEO of Small Cap Invest. “We are happy to come on board.”

Dr. Wendi Rodriugeza has been a member of the Company’s board of directors for over 5 years. She will be issued 150,000 options. These options will be fully vested when issued and may be exercised at any time up to 5 years.

### **ABOUT PACIFIC THERAPEUTICS LTD.**

The Company’s lead programs focus on erectile dysfunction and diseases of excessive scarring (fibrosis). The Company’s strategy includes reformulating approved drugs to increase efficacy and patient compliance, while reducing side effects, as well as completing the further clinical testing, manufacturing and other regulatory requirements sufficient to seek marketing

409 Granville Street Suite 1023, Vancouver, BC V6C 1T2  
Ph: (604) 738-1049 Fax: (604) 738-1094

authorizations. This strategy may reduce the risk, time and cost of developing therapies by avoiding the risks associated with basic research and using compounds with unknown safety and toxicity profiles.

The Company's lead drug candidate for fibrosis (progressive scarring of the organ), PTL-202 is a combination of Pentoxifylline and N-Acetyl-Cysteine (NAC) an amino acid and an extremely potent and important antioxidant. The positive results from the phase 1 clinical trial of PTL-202 and excellent pre-clinical results, will lead to further development of the product for treating fibrosis such as Idiopathic Pulmonary Fibrosis and Liver Cirrhosis. Both indications are large market opportunities with estimated markets in excess of \$1 billion.

The value of a treatment for fibrosis was recently confirmed by the \$8.3 billion acquisition of InterMune Inc. by Roche Holdings.

In 2011 the total market for drugs to treat erectile dysfunction ("ED") exceeded \$5 billion (New York Times, April 13, 2011, Duff Wilson). Pacific Therapeutics Ltd. has finalized a definitive agreement to license an oral dissolving technology ("sublingual formulation") of an approved drug to treat erectile dysfunction (ED).

The Company plans to build on the already significant development of the sublingual treatment for ED with the initiation of a pivotal Bioequivalence trial. The planned trial will enrol 24 individuals and should only take 4 months for completion. With successful results from this trial the Company will begin the application for marketing approval of this novel formulation to treat ED.

For further information visit our website at [www.pacifictherapeutics.com](http://www.pacifictherapeutics.com) or email us at [doug.unwin@pacifictherapeutics.com](mailto:doug.unwin@pacifictherapeutics.com)

Douglas H. Unwin, CEO & President  
(604) 738-1049  
[doug.unwin@pacifictherapeutics.com](mailto:doug.unwin@pacifictherapeutics.com)

#### **FORWARD LOOKING STATEMENTS**

Certain statements included in this press release constitute forward-looking information or statements (collectively, "forward-looking statements"), including those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", "may", "should" and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.

Readers should not place undue reliance on the Company's forward-looking statements, as the Company's actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements if known or unknown risks, uncertainties or other factors affect the Company's business, or if the Company's estimates or assumptions prove inaccurate. Therefore, the Company cannot provide any assurance that such forward-looking statements will materialize. The Company does not undertake to update any forward-looking information, except as, and to the extent required by, applicable securities laws.

409 Granville Street Suite 1023, Vancouver, BC V6C 1T2  
Ph: (604) 738-1049 Fax: (604) 738-1094